Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 1, 2009, Pages 5-9

  Joshua, Anthony M ^a   Ezzat, Shereen ^a   Asa, Sylvia L ^b   Evans, Andrew ^b   Broom, Reuben ^a   Freeman, Marc ^b   Knox, Jennifer J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; ETOPOSIDE; PRAZOSIN; SOMATOSTATIN DERIVATIVE; SUNITINIB; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RELAPSE; CANCER TISSUE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DNA DETERMINATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEMALE; FLANK PAIN; HUMAN; HUMAN TISSUE; HYPERTENSION; LAMINECTOMY; LYMPHADENECTOMY; MALE; METASTASIS; MISSENSE MUTATION; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUTROPENIA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RASH; SPINAL CORD COMPRESSION; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 58149385799     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1836     Document Type: Article

References (27)

1. DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds 2004 Pathology and genetics of tumours of endocrine organs. World Health Organization classification of tumours. Lyon, France: IARC Press
2. Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdlic CM, Savul SA, McLeod DR, Yee HA, Brackmann DE, Slattery 3rd WH, Myers EN, Ferrell RE, Rubinstein WS 2002 Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 39:178-183
3. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myossiorek, D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, Richard 3rd CW, Cornelisse CJ, Devilee P, Devlin B 2004 Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848-851
4. Astuti D, Douglas F, Lennard TW, Aligianis IA, Woodward ER, Evans DG, Eng C, Latif F, Maher ER 2001 Germline SDHD mutation in familial phaeochromocytoma. Lancet 357:1181-1182
5. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C, Maher ER 2001 Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet [Erratum (2002) 70:565] 69:49-54
6. Nakane M, Takahashi S, Sekine I, Fukui I, Koizumi M, Kage K, Ito Y, Aiba K, Horikoshi N, Hatake K, Ishikawa Y, Ogata E 2003 Successful treatment of malignant phaeochromocytoma with combination chemotherapy containing anthracycline. Ann Oncol 14:1449-1451
7. Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, Pacak K, Fojo T 2008 Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113:2020-2028
8. Fitoussi O, Debled M, Masson B, Coindre JM, Kantor G, Bui BN 1999 Advanced paraganglioma: a role for chemotherapy? Med Paediatr Oncol 33:129-131
9. Pipas JM, Krywicki RF 2000 Treatment of progressive metastatic glomus jugulare tumor (paraganglioma) with gemcitabine. Neuro Oncol 2:190-191
10. Kruijtzer CM, Beijnen JH, Swart M, Schellens JH 2000 Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature. Cancer Chemother Pharmacol 45:428-431
11. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB 2007 The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 14:569-585
12. Yao JC, Hoff PM 2007 Molecular targeted therapy for neuroendocrine tumors. Hematol Oncol Clin North Am 21:575-581
13. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS 2006 Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401-406
14. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F 2008 Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumours: results of a phase II study. J Clin Oncol 26:4311-4318
15. Anthony L, Chester M, Michael S, O'Dorisio TM, O'Dorisio MS 2008 Phase II open-label clinical trial of vatalanib (PTK/ZK) in patients with progressive neuroendocrine cancer. J Clin Oncol 26(Suppl): (Abstract)
16. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS 2008 Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403-3410
17. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
18. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, Tomlinson IP 2005 Accumulation of Krebs cycle intermediates and overexpression of HIF1α in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231-2239
19. Dahia PL; Familial Pheochromocytoma Consortium 2006 Transcription association of VHL and SDH mutations link hypoxia and oxidoreductase signals in pheochromocytomas. Ann NY Acad Sci 1073:208-220
20. Maxwell PH, Wiesener MS, Chang GW, Clifford, SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275
21. 2-regulated prolyl hydroxylation. Science 292:468-472
22. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield, KD, Pan Y, Simon MC, Thompson CB, Gottlieb E 2005 Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7:77-85
23. Ramensky V, Bork P, Sunyaev S 2002 Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894-3900
24. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O, Henley D, Herman P, Murday V, Niccoli-Sire P, Pasieka JL, Rohmer V, Tucker K, Jeunemaitre X, Marsh DJ, Plouin PF, Robinson BG 2006 Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91:827-836
25. Zhu X, Stergiopoulos K, Wu S 2008 Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 27:1-9
26. Roodhart JM, Langenberg MH, Witteveen E, Voest EE 2008 The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 3:132-143
27. Adams VR, Leggas M 2007 Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 29:1338-1353